Advertisement

BioDrugs

, Volume 13, Issue 5, pp 335–346 | Cite as

Timing of Vaccinations in Premature Infants

  • Carl T. D’Angio
  • Caroline B. Hall
Review Article

Abstract

Preterm infants have immunological immaturities that may impact on vaccine responses. Larger premature infants mount immune responses to vaccines that are similar to those of full term infants, but very premature infants (<30 weeks’ gestation at birth) have specific defects in vaccine responsiveness. The immunogenicity of diphtheria, tetanus and pertussis antigens is similar in full term and premature infants. Poliovirus vaccines, however, do not always stimulate adequate antibody responses in premature infants. The immunogenicity of Haemophilus influenzae type b conjugate vaccines varies widely in studies of premature infants, and may be affected both by choice of conjugate protein and by the infant’s overall health. Hepatitis B vaccine given at birth appears poorly immunogenic in infants with birthweights <1750g, with delay in the administration of the first dose yielding improved immunogenicity. Sick premature infants may suffer increased episodes of apnoea following vaccine administration. Persistence of immunity, the quality of the immune response, and evaluation of the specific tolerability and immunogenicity of new vaccines in premature infants are topics needing further research. Although it is generally true that recommendations for vaccination of term infants are applicable to premature infants, it is not always specifically true. Optimal care of preterm infants requires attention to the exceptions to this generalisation.

Keywords

Premature Infant Pertussis Diphtheria Term Infant Bacille Calmette Guerin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Committee on Infectious Diseases, American Academy of Pediatrics. Immunization in special circumstances. In: Peter G, editor. 1997 Red book: report of the committee on infectious diseases. 24th ed. Elk Grove Village (IL): American Academy of Pediatrics, 1997: 48Google Scholar
  2. 2.
    Siegrist CA. Vaccination strategies for children with specific medical conditions: a paediatrician’s viewpoint. Eur J Pediatr 1997; 156 (12): 899–904PubMedCrossRefGoogle Scholar
  3. 3.
    Joint Commission on Immunization and Vaccination. Immunization against infectious disease. London: HM Stationery Office, 1988Google Scholar
  4. 4.
    Schelonka RL, Infante AJ. Neonatal immunology. Semin Perinatol 1998; 22 (1): 2–14PubMedCrossRefGoogle Scholar
  5. 5.
    Maccario R, Chirico G, Mingrat G, et al. Expression of CD45R0 antigen on the surface of resting and activated neonatal T lymphocyte subsets. Biol Neonate 1993; 64 (6): 346–53PubMedCrossRefGoogle Scholar
  6. 6.
    Moretta A, Valtorta A, Chirico G, et al. Lymphocyte subpopulations in preterm infants: high percentage of cells expressing P55 chain of interleukin-2 receptor. Biol Neonate 1991; 59 (4): 213–8PubMedCrossRefGoogle Scholar
  7. 7.
    Bessler H, Sirota L, Notti I, et al. IL-2 receptor gene expression and IL-2 production by human preterm newborns’ cells. Clin Exp Immunol 1993; 93 (3): 479–83PubMedCrossRefGoogle Scholar
  8. 8.
    Kumar A, Jauhari P, Singh U, et al. Quantitation of T cells in venous blood of healthy neonates. Indian J Pediatr 1994; 61 (6): 711–4PubMedCrossRefGoogle Scholar
  9. 9.
    Series IM, Pichette J, Carrier C, et al. Quantitative analysis of T and B cell subsets in healthy and sick premature infants. Early Hum Dev 1991; 26 (2): 143–54PubMedCrossRefGoogle Scholar
  10. 10.
    Gavin MA, Bevan MJ. Increased peptide promiscuity provides a rationale for the lack of N regions in the neonatal T cell repertoire. Immunity 1995; 3 (6): 793–800PubMedCrossRefGoogle Scholar
  11. 11.
    Schroeder Jr HW, Mortari F, Shiokawa S, et al. Developmental regulation of the human antibody repertoire. Ann N Y Acad Sci 1995; 764: 242–60PubMedCrossRefGoogle Scholar
  12. 12.
    Veber MB, Cunningham-Rundles S, Schulman M, et al. Acute shift in immune response to microbial activators in very-low-birth-weight infants. Clin Exp Immunol 1991; 83 (3): 391–5PubMedCrossRefGoogle Scholar
  13. 13.
    Daum RS, Siber GR, Ballanco GA, et al. Serum anticapsular antibody response in the first week after immunization of adults and infants with the Haemophilus influenzae type b-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Infect Dis 1991; 164 (6): 1154–9PubMedCrossRefGoogle Scholar
  14. 14.
    Barington T, Gyhrs A, Kristensen K, et al. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun 1994; 62 (1): 9–14PubMedGoogle Scholar
  15. 15.
    Dancis J, Osborn JJ, Kunz HK. Studies of the immunology of the newborn infant. IV Antibody formation in the premature infant. Pediatrics 1953; 12: 151–7PubMedGoogle Scholar
  16. 16.
    Cates KL, Goetz C, Rosenberg N, et al. Longitudinal development of specific and functional antibody in very low birth weight premature infants. Pediatr Res 1988; 23 (1): 14–22PubMedCrossRefGoogle Scholar
  17. 17.
    Bernbaum J, Anolik R, Polin RA, et al. Development of the premature infant’s host defense system and its relationship to routine immunizations. Clin Perinatol 1984; 11 (1): 73–84PubMedGoogle Scholar
  18. 18.
    Committee on Infectious Diseases, American Academy of Pediatrics. Report of the Committee on Infectious Disease. 19th ed. Evanston (IL): American Academy of Pediatrics, 1982Google Scholar
  19. 19.
    Vohr BR, Oh W. Age of diphtheria, tetanus, and pertussis immunization of special care nursery graduates. Pediatrics 1986; 77 (4): 569–71PubMedGoogle Scholar
  20. 20.
    Magoon MW, Belardo LJ, Caldito G. Delays in immunizations of high-risk infants during the first two years of life: special care for the high-risk infant should not mean special immunization schedules. J Perinatol 1995; 15 (3): 222–8PubMedGoogle Scholar
  21. 21.
    Langkamp DL, Langhough R. Primary care physicians’ knowledge about diphtheria-tetanus-pertussis immunizations in preterm infants. Pediatrics 1992; 89 (1): 52–5PubMedGoogle Scholar
  22. 22.
    Wilkins J. Immunologic response to various regimens of pertussis vaccine. Fourth Annual Immunization Conference; 1967: San Antonio (TX): U.S. Department of Health, Education and Welfare, 1967: 43–5Google Scholar
  23. 23.
    Smolen P, Bland R, Heiligenstein E, et al. Antibody response to oral polio vaccine in premature infants. J Pediatr 1983; 103 (6): 917–9PubMedCrossRefGoogle Scholar
  24. 24.
    Bernbaum JC, Daft A, Anolik R, et al. Response of preterm infants to diphtheria-tetanus-pertussis immunizations. J Pediatr 1985; 107 (2): 184–8PubMedCrossRefGoogle Scholar
  25. 25.
    Conway SP, James JR, Smithells RW, et al. Immunisation of the preterm baby [letter]. Lancet 1987; 2 (8571): 1326PubMedCrossRefGoogle Scholar
  26. 26.
    Koblin BA, Townsend TR, Munoz A, et al. Response of preterm infants to diphtheria-tetanus-pertussis vaccine. Pediatr Infect Dis J 1988; 7 (10): 704–11PubMedCrossRefGoogle Scholar
  27. 27.
    Pullan CR, Hull D. Routine immunisation of preterm infants. Arch Dis Child 1989; 64 (10): 1438–41PubMedCrossRefGoogle Scholar
  28. 28.
    Bernbaum J, Daft A, Samuelson J, et al. Half-dose immunization for diphtheria, tetanus, pertussis: response of preterm infants. Pediatrics 1989; 83 (4): 471–6PubMedGoogle Scholar
  29. 29.
    Conway S, James J, Balfour A, et al. Immunisation of the preterm baby. J Infect 1993; 27 (2): 143–50PubMedCrossRefGoogle Scholar
  30. 30.
    D’Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics 1995; 96 (1 Pt 1): 18–22PubMedGoogle Scholar
  31. 31.
    Faldella G, Alessandroni R, Magini GM, et al. The preterm infant’s antibody response to a combined diphtheria, tetanus, acellular pertussis and hepatitis B vaccine. Vaccine 1998; 16 (17): 1646–9PubMedCrossRefGoogle Scholar
  32. 32.
    Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334 (6): 341–8PubMedCrossRefGoogle Scholar
  33. 33.
    Schloesser RL, Fischer D, Otto W, et al. Safety and immunogenicity of an acellular pertussis vaccine in premature infants. Pediatrics 1999; 103 (5): 60CrossRefGoogle Scholar
  34. 34.
    Committee on Infectious Diseases, American Academy of Pediatrics. Poliomyelitis prevention: revised recommendations for use of inactivated and live oral poliovirus vaccines. Pediatrics 1999; 103 (1): 171–2CrossRefGoogle Scholar
  35. 35.
    Recommendations of the Advisory Committee on Immunization Practices: revised recommendations for routine poliomyelitis vaccination. MMWR Morb Mortal Wkly Rep 1999; 48 (27): 590Google Scholar
  36. 36.
    O’Shea TM, Dillard RG, Gillis DC, et al. Low rate of response to enhanced inactivated polio vaccine in preterm infants with chronic illness. Clin Res Regul Affairs 1993; 10 (1): 49–57CrossRefGoogle Scholar
  37. 37.
    Adenyi-Jones SC, Faden H, Ferdon MB, et al. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 1992; 120 (5): 686–9PubMedCrossRefGoogle Scholar
  38. 38.
    Salk J, Stoeckel P, van Wezel AL, et al. Antigen content of inactivated poliovirus vaccine for use in a one-or two-dose regimen. Ann Clin Res 1982; 14 (5–6): 204–12PubMedGoogle Scholar
  39. 39.
    Hardy Jr GE, Hopkins CC, Linnemann Jr CC, et al. Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules. Pediatrics 1970; 45 (3): 444–8PubMedGoogle Scholar
  40. 40.
    McBean AM, Thoms ML, Albrecht P, et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988; 128 (3): 615–28PubMedGoogle Scholar
  41. 41.
    Faden H, Modlin JF, Thoms ML, et al. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990; 162 (6): 1291–7PubMedCrossRefGoogle Scholar
  42. 42.
    Washburn LK, TM OS, Gillis DC, et al. Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr 1993; 123 (5): 791–4PubMedCrossRefGoogle Scholar
  43. 43.
    Munoz A, Salvador A, Brodsky NL, et al. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. Pediatrics 1995; 96 (2 Pt 1): 216–9PubMedGoogle Scholar
  44. 44.
    Kristensen K, Gyhrs A, Lausen B, et al. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J 1996; 15 (6): 525–9PubMedCrossRefGoogle Scholar
  45. 45.
    Kayhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994; 22 (4): 397–402PubMedCrossRefGoogle Scholar
  46. 46.
    Madore DV, Johnson CL, Phipps DC, et al. Safety and immunologic response to Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in 1-to 6-month-old infants. Pediatrics 1990; 85 (3): 331–7PubMedGoogle Scholar
  47. 47.
    Santosham M, Hill J, Wolff M, et al. Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population [published erratum appears in Pediatr Infect Dis J 1991 May; 10 (5): 369]. Pediatr Infect Dis J 1991; 10 (2): 113–7PubMedCrossRefGoogle Scholar
  48. 48.
    Black SB, Shinefield HR, Lampert D, et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10 (2): 92–6PubMedCrossRefGoogle Scholar
  49. 49.
    Kayhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147 (6): 1100PubMedCrossRefGoogle Scholar
  50. 50.
    Decker MD, Edwards KM, Bradley R, et al. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120 (2 Pt 1): 184–9PubMedCrossRefGoogle Scholar
  51. 51.
    Chawareewong S, Jirapongsa A, Lokaphadhana K. Immune response to hepatitis B vaccine in premature neonates. Southeast Asian J Trop Med Public Health 1991; 22 (1): 39–40PubMedGoogle Scholar
  52. 52.
    del Canho R, Grosheide PM, Gerards LJ, et al. Hepatitis B vaccination and preterm infants. Pediatr Infect Dis J 1993; 12 (5): 407–8PubMedCrossRefGoogle Scholar
  53. 53.
    Belson A, Reif S, Peled Y, et al. Immune response to hepatitis B virus vaccine in 1-year-od preterm and term infants. J Pediatr Gastroenterol Nutr 1996; 23 (3): 252–5PubMedCrossRefGoogle Scholar
  54. 54.
    Belloni C, Chirico G, Pistorio A, et al. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatr 1998; 87 (3): 336–8PubMedCrossRefGoogle Scholar
  55. 55.
    Blondheim O, Bader D, Abend M, et al. Immunogenicity of hepatitis B vaccine in preterm infants. Arch Dis Childhood Fetal Neonatal Ed 1998; 79 (3): F206–8CrossRefGoogle Scholar
  56. 56.
    Lau YL, Tam AY, Ng KW, et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992; 121 (6): 962–5PubMedCrossRefGoogle Scholar
  57. 57.
    Kim SC, Chung EK, Hodinka RL, et al. Immunogenicity of hepatitis B vaccine in preterm infants. Pediatrics 1997; 99 (4): 534–6PubMedCrossRefGoogle Scholar
  58. 58.
    Patel DM, Butler J, Feldman S, et al. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr 1997; 131 (4): 641–3PubMedCrossRefGoogle Scholar
  59. 59.
    Huang FY, Lee PI, Lee CY, et al. Hepatitis B vaccination in preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 77 (2): F135–8PubMedCrossRefGoogle Scholar
  60. 60.
    Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999; 103 (2): 14CrossRefGoogle Scholar
  61. 61.
    Golebiowska M, Kardas-Sobantka D, Chlebna-Sokol D, et al. Hepatitis B vaccination in preterm infants. Eur J Pediatr 1999; 158 (4): 293–7PubMedCrossRefGoogle Scholar
  62. 62.
    Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 1999; 48 (26): 563–5Google Scholar
  63. 63.
    Thimerosal in vaccines —an interim report to clinicians. Pediatrics 1999; 104 (3): 570–4Google Scholar
  64. 64.
    Sedaghatian MR, Hashem F, Moshaddeque Hossain M. Bacille Calmette Guerin vaccination in pre-term infants. Int J Tuberc Lung Dis 1998; 2 (8): 679–82PubMedGoogle Scholar
  65. 65.
    Sedaghatian MR, Kardouni K. Tuberculin response in preterm infants after BCG vaccination at birth. Arch Dis Child 1993; 69 (3 Spec No): 309–11PubMedCrossRefGoogle Scholar
  66. 66.
    Thayyil-Sudhan S, Kumar A, Singh M, et al. Safety and effectiveness of BCG vaccination in preterm babies. Arch Dis Child Fetal Neonatal Ed 1999; 81: F64–6PubMedCrossRefGoogle Scholar
  67. 67.
    Groothuis JR, Levin MJ, Lehr MV, et al. Immune response to split-product influenza vaccine in preterm and full-term young children. Vaccine 1992; 10 (4): 221–5PubMedCrossRefGoogle Scholar
  68. 68.
    Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997; 100 (6): 937–42PubMedCrossRefGoogle Scholar
  69. 69.
    Saez-Llorens X, Castano E, Null D, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17 (9): 787–91PubMedCrossRefGoogle Scholar
  70. 70.
    Thakur BK, Wu LR, Schaeufele JE RSV-IGIV therapy: a cost/benefit analysis [letter]. Pediatrics 1997; 100 (3 Pt 1): 417–8PubMedCrossRefGoogle Scholar
  71. 71.
    Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study. J Paediatr Child Health 1997; 33 (5): 418–21PubMedCrossRefGoogle Scholar
  72. 72.
    Sanchez PJ, Laptook AR, Fisher L, et al. Apnea after immunization of preterm infants. J Pediatr 1997; 130 (5): 746–51PubMedCrossRefGoogle Scholar
  73. 73.
    Pourcyrous M, Korones SB, Crouse D, et al. Interleukin-6 C-reactive protein, and abnormal cardiorespiratory responses to immunization in premature infants. Pediatrics 1998; 101 (3): E3PubMedCrossRefGoogle Scholar
  74. 74.
    Topsis J, Kandall S, Weinstein J, et al. Tolerance of initial diphtheria-tetanus-pertussis immunization in preterm infants. J Perinatol 1996; 16 (2 Pt 1): 98–102PubMedGoogle Scholar
  75. 75.
    Slack MH, Schapira D. Severe apnoeas following immunisation in premature infants. Arch Dis Child Fetal Neonatal Ed 1999; 81: F67–8PubMedCrossRefGoogle Scholar
  76. 76.
    Botham SJ, Isaacs D. Incidence of apnoea and bradycardia in preterm infants following triple antigen immunization. J Paediatr Child Health 1994; 30 (6): 533–5PubMedCrossRefGoogle Scholar
  77. 77.
    Robinson MJ, Campbell F, Powell P, et al. Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1999; 80 (1): F69–71PubMedCrossRefGoogle Scholar
  78. 78.
    Weinberg GA, Einhorn MS, Lenoir AA, et al. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr 1987; 111 (1): 22–7PubMedCrossRefGoogle Scholar
  79. 79.
    Khalak R, Pichichero ME, D’Angio CT. Three-year follow-up of vaccine response in extremely preterm infants. Pediatrics 1998; 101 (4 Pt 1): 597–603PubMedCrossRefGoogle Scholar
  80. 80.
    Lieberman JM, Greenberg DP, Wong VK, et al. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J Pediatr 1995; 126 (2): 198–205PubMedCrossRefGoogle Scholar
  81. 81.
    Linder N, Yaron M, Handsher R, et al. Early immunization with inactivated poliovirus vaccine in premature infants. J Pediatr 1995; 127 (1): 128–30PubMedCrossRefGoogle Scholar
  82. 82.
    Eskola J, Kayhty H. Early immunization with conjugate vaccines. Vaccine 1998; 16 (14–15): 1433–8PubMedCrossRefGoogle Scholar
  83. 83.
    Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998; 177 (4): 1112–5PubMedCrossRefGoogle Scholar
  84. 84.
    Madore DV. Characterization of immune response as an indicator of Haemophilus influenzae type b vaccine efficacy. Pediatr Infect Dis J 1998; 17 (9 Suppl. ): 207S–10SGoogle Scholar
  85. 85.
    Daum RS. Efficacy of the combined diphtheria-tetanus toxoids-pertussis-Haemophilus conjugate vaccine. Pediatr Infect Dis J 1995; 14 (7): 640–1PubMedCrossRefGoogle Scholar
  86. 86.
    Zepp F, Schmitt HJ, Kaufhold A, et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr 1997; 156 (1): 18–24PubMedCrossRefGoogle Scholar
  87. 87.
    Sood SK, Ballanco GA, Daum RS. Duration of serum anticapsular antibody after a two-dose regimen of a Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine and anamnestic response after a third dose. J Pediatr 1991; 119 (4): 652–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Strong Children’s Research Center, Department of PaediatricsUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations